Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 2013. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibility (PDMRs) related to the GSK 401K plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding a specific internal plan transaction rather than a financial results report.
Material Changes
The filing details a revaluation of the cash element of the notional investment held within the GSK 401K plan. On November 8, 2013, this revaluation resulted in an increase in the notional allocation of GSK American Depositary Shares (ADSs) at a price of $53.16 per ADS.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly reports a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).
Key Facts for Investor Verification
- Transaction Date: November 8, 2013.
- Notification Date: November 11, 2013.
- Instrument: GSK American Depositary Shares (ADSs).
- Price per ADS: $53.16.
- Parties Involved: Dr. M. Slaoui and Dr. K. Slaoui (Connected Person).
- Change in Allocation: An increase of 4 ADSs was recorded for the Connected Person.